Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients

Abstract

Platinum drugs are among the most active and widely used agents in the treatment of different cancers. However, the great individual variability in both outcome and toxicity of platinum chemotherapy requires the identification of genetic markers that can be used to screen patients before treatment. In this study, 21 polymorphisms in 10 genes, the protein activities of which may be addressed in different aspects of cisplatin metabolism, were tested for correlations with efficacy and toxicity of cisplatin–cyclophosphamide regimen in 104 ovarian cancer patients. The glutathione S-transferase P1 (GSTP1) Ile105Val polymorphism was strongly associated with progression-free survival (χ2=12.12, P=0.002). The allelic status of the GSTA1 –69 C>T polymorphism correlated with the overall survival: patients with T/T genotype survived longer than C/C carriers (P=0.044). Thrombocytopenia, anemia and neuropathy were less frequent among patients with the GSTM1-null or GSTM3 intron 6 AGG/AGG genotypes. Severe neutropenia was associated with the TP53 72 Pro/Pro, XPD 312 Asp/Asn and XRCC1 399 Arg/Arg genotypes. A higher risk of nephrotoxicity was noted for patients with the heterozygous ERCC1 19007 T/C and 8092 C/A genotypes. No correlations were found between genotypes and complete tumor responses.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573–584.

    Article  CAS  PubMed  Google Scholar 

  2. Rabik CA, Dolan ME . Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9–23.

    Article  CAS  PubMed  Google Scholar 

  3. Evans WE, McLeod HL . Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538–548.

    Article  CAS  PubMed  Google Scholar 

  4. Yamayoshi Y, Iida E, Tanigawara Y . Cancer pharmacogenomics: international trends. Int J Clin Oncol 2005; 10: 5–13.

    Article  PubMed  Google Scholar 

  5. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16: 555–560.

    CAS  PubMed  Google Scholar 

  6. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000; 9: 843–847.

    CAS  PubMed  Google Scholar 

  7. Au WW, Salama SA, Sierra-Torres SH . Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111: 1843–1850.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, Abdel-Rahman SZ . Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics 2007; 17: 897–905.

    Article  CAS  PubMed  Google Scholar 

  9. Jung Y, Lippard SJ . Direct cellular responses to platinum-induced DNA damage. Chem Rev 2007; 107: 1387–1407.

    Article  CAS  PubMed  Google Scholar 

  10. Boulikas T, Vougiouka M . Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10: 1663–1682.

    CAS  PubMed  Google Scholar 

  11. McIlwain CC, Townsend DM, Tew KD . Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006; 25: 1639–1648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ishimoto TM, Ali-Osman F . Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 2002; 12: 543–553.

    Article  CAS  PubMed  Google Scholar 

  13. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS . Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008; 7: 3247–3255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936–942.

    Article  CAS  PubMed  Google Scholar 

  15. Howells RE, Dhar KK, Hoban PR, Jones PW, Fryer AA, Redman CW et al. Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14: 242–250.

    Article  CAS  PubMed  Google Scholar 

  16. Lee JM, Wu MT, Lee YC, Yang SY, Chen JS, Hsu HH et al. Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 2005; 11: 4749–4753.

    Article  CAS  PubMed  Google Scholar 

  17. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006; 100: 330–337.

    Article  CAS  PubMed  Google Scholar 

  18. Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R et al. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340: 256–262.

    Article  CAS  PubMed  Google Scholar 

  19. Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM . The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 2007; 43: 283–290.

    Article  CAS  PubMed  Google Scholar 

  20. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007; 107: S223–S229.

    Article  PubMed  Google Scholar 

  21. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007; 25: 5172–5179.

    Article  CAS  PubMed  Google Scholar 

  22. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 1247–1254.

    Article  CAS  PubMed  Google Scholar 

  23. Milligan BG . Total DNA isolation. In: Hoelzel AR (ed). Molecular Genetic Analysis of Populations. Oxford University Press: London, 1998. pp 29–60.

    Google Scholar 

  24. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001; 11: 663–669.

    Article  CAS  PubMed  Google Scholar 

  25. Tetlow N, Robinson A, Mantle T, Board P . Polymorphism of human mu class glutathione transferases. Pharmacogenetics 2004; 14: 359–368.

    Article  CAS  PubMed  Google Scholar 

  26. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T et al. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 693–696.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Saarikoski ST, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C et al. Combined effect of polymorphic gst genes on individual susceptibility to lung cancer. Int J Cancer 1998; 77: 516–521.

    Article  CAS  PubMed  Google Scholar 

  28. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939–4943.

    Article  CAS  PubMed  Google Scholar 

  29. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001; 22: 1437–1445.

    Article  CAS  PubMed  Google Scholar 

  30. Tuimala J, Szekely G, Gundy S, Hirvonen A, Norppa H . Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis 2002; 23: 1003–1008.

    Article  CAS  PubMed  Google Scholar 

  31. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E . The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002; 100: 3761–3766.

    Article  CAS  PubMed  Google Scholar 

  32. Sjalander A, Birgander R, Kivela A, Beckman G . p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995; 45: 144–149.

    Article  CAS  PubMed  Google Scholar 

  33. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ . Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000; 53: 88–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Fritsche E, Pittman GS, Bell DA . Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene. Mutat Res 2000; 432: 1–5.

    CAS  PubMed  Google Scholar 

  35. Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, Bingham SA . Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 2001; 22: 1053–1060.

    Article  CAS  PubMed  Google Scholar 

  36. Khrunin AV, Khokhrin DV, Limborska SA . Glutathione-S-transferase gene polymorphism in Russian populations of European part of Russia. Genetika 2008; 44: 1429–1434.

    CAS  PubMed  Google Scholar 

  37. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R . Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007; 25: 4528–4535.

    Article  CAS  PubMed  Google Scholar 

  38. Goodisman J, Hagrman D, Tacka KA, Souid AK . Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 2006; 57: 257–267.

    Article  CAS  PubMed  Google Scholar 

  39. Ping J, Wang H, Huang M, Liu ZS . Genetic analysis of glutathione S-transferase A1 polymorphism in the Chinese population and the influence of genotype on enzymatic properties. Toxicol Sci 2006; 89: 438–443.

    Article  CAS  PubMed  Google Scholar 

  40. Dirven HA, van Ommen B, van Bladeren PJ . Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994; 54: 6215–6220.

    CAS  PubMed  Google Scholar 

  41. Dirven HA, van Ommen B, van Bladeren PJ . Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 1996; 9: 351–360.

    Article  CAS  PubMed  Google Scholar 

  42. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003; 103: 810–814.

    Article  CAS  PubMed  Google Scholar 

  43. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA . Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 3050–3056.

    Article  CAS  PubMed  Google Scholar 

  44. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD . Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25: 708–714.

    Article  CAS  PubMed  Google Scholar 

  45. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000; 11: 639–643.

    Article  CAS  PubMed  Google Scholar 

  46. Rosell R, Taron M, Camps C, López-Vivanco G . Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 2003; 39: 775–786.

    Article  CAS  Google Scholar 

  47. Gossage L, Madhusudan S . Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 2007; 11: 361–380.

    Article  CAS  PubMed  Google Scholar 

  48. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002; 94: 681–690.

    Article  CAS  PubMed  Google Scholar 

  49. Bojesen SE, Nordestgaard BG . The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 2008; 7: 158–163.

    Article  CAS  PubMed  Google Scholar 

  50. Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS . Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 2006; 132: 521–528.

    Article  CAS  PubMed  Google Scholar 

  51. Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S et al. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 2006; 26: 687–693.

    CAS  PubMed  Google Scholar 

  52. Liu H, Baliga M, Baliga R . Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res 2002; 22: 863–868.

    PubMed  Google Scholar 

  53. Liu H, Baliga R . Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 2003; 63: 1687–1696.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the programs of the Russian Academy of Sciences ‘Molecular and Cell Biology’ and ‘Fundamental Science for Medicine’, Program of Support for Leading Scientific Schools of the Ministry of Science and Technology of the Russian Federation, Russian Foundation for Basic Research (Grant No. 08-04-01313-a) and the Grant of the President of the Russian Federation for Support for Young Scientists (Grant No. MK-3955.2007.4).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A V Khrunin.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (http://www.nature.com/tpj)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khrunin, A., Moisseev, A., Gorbunova, V. et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10, 54–61 (2010). https://doi.org/10.1038/tpj.2009.45

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2009.45

Keywords

This article is cited by

Search

Quick links